Poop pills could tame rare liver disease
NCT ID NCT07477782
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether fecal microbiota transplantation (FMT) can improve liver function in people with primary sclerosing cholangitis (PSC) and inflammatory bowel disease (IBD). 72 participants will receive either FMT or a sham procedure via colonoscopy and later oral capsules. The main goal is to lower certain liver enzymes and bilirubin levels after 48 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- fecal microbiota transplantation (FMT)
- What this could lead to
- If successful, FMT could offer a new way to control PSC and reduce the need for liver transplants.
- What could go wrong
- This is an early phase 2 trial with only 72 people. The treatment may not work, and there are risks from the colonoscopy and oral capsules.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INFLAMMATORY BOWEL DISEASE (IBD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hepatology Department, Saint Antoine Hospital
Paris, 75012, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a new pill tame inflammatory bowel disease? early safety trial begins
- Can a mediterranean diet and Time-Restricted eating tame gut inflammation?
- Could early lipid screening in High-Risk kids prevent future heart attacks?
- Two-Drug cocktail aims to tame stubborn Crohn's disease
- Dutch hospital data reveals hidden patterns in IBD treatment
- Acupuncture points may signal hidden disease activity